MSLN and mesothelioma: Thus, the combination therapy of this novel vaccine with PD-1 blockade may have great potential as a new treatment strategy for the treatment of other cancers, such as mesothelioma, pancreatic cancer, ovarian cancer and triple negative breast cancer with high expression of MSLN.